Zdrowie i gospodarka · 07/04/2014

FDA Clears Path for SKELAXIN Tablets, 400mg, to be Approved via Abbreviated New Drug Applications

The US Food and Drug Administration has made a determination that SKELAXIN tablets, 400mg, were not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications for the medication.